Innovation

The Hybrid Medical Solution

peyronies-h100-treatment-new

Hybrid Medical was founded to take advantage of its unique medical technology which can allow advanced transdermal delivery of drug therapy for treatment of disease. This may replace the use of needles and provide broader coverage of diseased tissue.

The first specific market the company will participate in is based on a unique invention designed to treat Peyronie’s disease. There is no dominant product for the treatment of this disease and the company has the opportunity to be the world market leader in this extremely large and underserved market.

The Hybrid Medical invention for the treatment of Peyronie’s disease is a new topically applied delivery system called H-100™ which combines an effective carrier agent with proven plaque reducing compounds. The initial Hybrid Medical product will be topically applied and is designed to maximize the curative drug delivery to the diseased tissue in a manner unprecedented in this industry.

Hybrid Medical plans on using its unique transdermal delivery system for similar purposes in combination with other drugs in the future for treatments of different diseases. For example, this could be extremely effective for treatment of conditions such as Dupuytren’s contracture.